Earlier today, Moderna and Merck presented 5-year follow-up data for intismeran autogene in combination with KEYTRUDA® (pembrolizumab) in patients with high-risk melanoma at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. Watch our latest IR Insights video below to hear more from our CEO Stéphane Bancel and Chief Development Officer David Berman about these results. #ASCO2026# #ASCO26#